Modeling cellular pharmacokinetics of 14- and 15-membered macrolides with physicochemical properties

Journal of Medicinal Chemistry

Volumn 54, Issue 3, 2011, Pages 719-733

  Stepanić, Viŝsnja ^a,b   Koŝstrun, Sanja ^a,c   Malnar, Ivica ^a,c   Hlevnjak, Mario ^a,d   Butković, Kristina ^a,c   Ćaleta, Irena ^a,c   Dukŝi, Marko ^a,c   Kragol, Goran ^a,c   Makaruha Stegić, Oresta ^e   Mikac, Lara ^a,b   Ralić, Jovica ^a,c   Tatić, Iva ^a,f   Tavćar, Branka ^a,c   Valko, Klara ^a   Zulfikari, Selvira ^h   Munić, Vesna ^a,c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c Galapagos Istra iva ki Centar DOO Ltd   (Croatia)

^d Mediterranean Institute for Life Sciences   (Croatia)

^e Axellia Pharmaceuticals Branch Zagreb   (Croatia)

^f

^g Croatia

^h Agency for Medicinal Products and Medical Devices   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE;

ARTICLE; CANCER CELL CULTURE; CELL TYPE; HUMAN; HUMAN CELL; LEUKOCYTE; LUNG CARCINOMA; PHYSICAL CHEMISTRY; PREDICTION;

EID: 79851496263     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101317f     Document Type: Article

References (51)

1. Whitman, M. S.; Tunkel, A. R. Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect. Control Hosp. Epidemiol. 1992, 13, 357-368.
2. Culic, O.; Erakovic, V.; Parnham, M. J. Anti-inflammatory effects of macrolide antibiotics. Eur. J. Pharmacol. 2001, 429, 209-229. (Pubitemid 33043997)
3. Shinkai, M.; Henke, M. O.; Rubin, B. K. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol. Ther. 2008, 117, 393-405.
4. Hamada, K.; Mikasa, K.; Yunou, Y.; Kurioka, T.; Majima, T.; Narita, N.; Kita, E. Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy 2000, 46, 49-61. (Pubitemid 30009334)
5. Mikasa, K.; Sawaki, M.; Kita, E.; Hamada, K.; Teramoto, S.; Sakamoto, M.; Maeda, K.; Konishi, M.; Narita, N. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. Chemotherapy 1997, 43, 288-296. (Pubitemid 27230874)
6. Andersen, S. L.; Oloo, A. J.; Gordon, D. M.; Ragama, O. B.; Aleman, G. M.; Berman, J. D.; Tang, D. B.; Dunne, M. W.; Shanks, G. D. Successful double-blinded, randomized, placebocontrolled field trial of azithromycin and doxycycline as prophylaxis for malaria in Western Kenya. Clin. Infect. Dis. 1998, 26, 146-150. (Pubitemid 28068169)
7. Taylor, W. R.; Richie, T. L.; Fryauff, D. J.; Picarima, H.; Ohrt, C.; Tang, D.; Braitman, D.; Murphy, G. S.; Widjaja, H.; Tjitra, E.; Ganjar, A.; Jones, T. R.; Basri, H.; Berman, J. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin. Infect. Dis. 1999, 28, 74-81. (Pubitemid 29246129)
8. Crosbie, P. A.; Woodhead, M. A. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur. Respir. J. 2009, 33, 171-181.
9. Bosnar, M.; Kelneric, Z.; Munic, V.; Erakovic, V.; Parnham, M. J. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob. Agents Chemother. 2005, 49, 2372-2377. (Pubitemid 40734469)
10. Miossec-Bartoli, C.; Pilatre, L.; Peyron, P.; N'Diaye, E. N. Collart-Dutilleul, V.; Maridonneau-Parini, I.; Diu-Hercend, A. The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells. Antimicrob. Agents Chemother. 1999, 43, 2457-2462. (Pubitemid 29471227)
11. Wildfeuer, A.; Laufen, H.; Muller-Wening, D.; Haferkamp, O. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. Arzneim.-Forsch. 1989, 39, 755-758. (Pubitemid 19176330)
12. Wildfeuer, A.; Reisert, I.; Laufen, H. Uptake and subcellular distribution of azithromycin in human phagocytic cells. Demonstration of the antibiotic in neutrophil polymorphonuclear leucocytes and monocytes by autoradiography and electron microscopy. Arzneim.-Forsch. 1993, 43, 484-486. (Pubitemid 23112991)
13. Carlier, M. B.; Zenebergh, A.; Tulkens, P. M. Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J. Antimicrob. Chemother. 1987, 20 (Suppl. B), 47-56. (Pubitemid 18003048)
14. Vazifeh, D; Abdelghaffar, H; Labro, M. T. Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin. Antimicrob. Agents Chemother. 1997, 41, 2099-2107. (Pubitemid 27422197)
15. McDonald, P. J.; Pruul, H. Phagocyte uptake and transport of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 1991, 10, 828-833.
16. Amsden, G. W. Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents 2001, 18 (Suppl. 1), S11-S15. (Pubitemid 33713497)
17. Jain, R.; Danziger, L. H. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr. Pharm. Des. 2004, 10, 3045-3053. (Pubitemid 39242900)
18. Ganesan, A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 2008, 12, 306-317.
19. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem. 2008, 51, 817-834. (Pubitemid 351304691)
20. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discovery 2007, 6, 881-890. (Pubitemid 350042396)
21. Mannhold, R; Poda, G. I.; Ostermann, C; Tetko, I. V. Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds. J. Pharm. Sci. 2009, 98, 861-893.
22. Girard,A. E.;Girard,D; English,A.R.;Gootz, T.D.;Cimochowski, C. R.; Faiella, J. A.; Haskell, S. L.; Retsema, J. A. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother. 1987, 31, 1948-1954. (Pubitemid 18009567)
23. Valko, K.; Bevan, C.; Reynolds, D. Chromatographic hydrophobicity index by fast-gradient RP-HPLC: a high-throughput alternative to logP/logD. Anal. Chem. 1997, 69, 2022-2029. (Pubitemid 127698689)
24. Valko, K.; Du, C. M.; Bevan, C. D.; Reynolds, D. P.; Abraham, M. H. Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. J. Pharm. Sci. 2000, 89, 1085-1096.
25. Djokic, S.; Kobrehel, G.; Lopotar, N.; Kamenar, B.; Nagl, A.; Mrvos, D. Synthesis and structure elucidation of 10-dihydro-10-deoxo-11-methyl-11- azaerythromycin A. J. Chem. Res., Synop. 1988, 152-153.
26. Morimoto, S.; Takahashi, Y.; Watanabe, Y.; Omura, S. Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J. Antibiot. (Tokyo) 1984, 37, 187-189. (Pubitemid 14195348)
27. Alihodzic, S.; Fajdetic, A.; Kobrehel, G.; Lazarevski, G.; Mutak, S.; Pavlovic, D.; Stimac, V.; Cipcic, H.; Kramaric,M.D.; Erakovic, V.; Hasenohrl, A.; Marsic, N.; Schoenfeld, W. Synthesis and antibacterial activity of isomeric 15-membered azalides. J Antibiot. (Tokyo) 2006, 59, 753-769. (Pubitemid 46212493)
28. Culic, O.; Bosnar, M.; Marjanovic, N.; Jelic, D.; Alihodzic, S.; Vela, V.; Marusic-Istuk, Z.; Erakovic, V.; Bosnjak, B.; Hrvacic, B.; Tomaskovic, M.; Munic, V.; Ivetic, V.; Hutinec, A.; Kragol, G.; Leljak, M. Macrolides with Anti-Inflammatory Activity. WO 2006087644, 2006.
29. Hall, L. H.; Kier, L. B.; Brown, B. B. Molecular similarity based on novel atom type electrotopological state indices. J. Chem. Inf. Comput. Sci. 1995, 35, 1074-1080.
30. Abraham, M. H.; Chadha, H. S.; Martins, F.; Mitchell, R. C.; Bradbury, M. W.; Gratton, J. A. Hydrogen bonding. Part 46: A review of the correlation and prediction of transport properties by an LFER method: physicochemical properties, brain penetration and skin permeability. Pestic. Sci. 1999, 55, 78-88. (Pubitemid 29090796)
31. Platts, J. A.; Abraham, M. H.; Butina, D.; Hersey, A. Estimation of molecular linear free energy relation descriptors using a group contribution approach. J. Chem. Inf. Comput. Sci. 1999, 39, 835-845.
32. Zhao, Y. H.; Abraham, M. H.; Hersey, A.; Luscombe, C. N. Quantitative relationship between rat intestinal absorption and Abraham descriptors. Eur. J. Med. Chem. 2003, 38, 939-947. (Pubitemid 37452421)
33. Hollosy, F.; Valko, K.; Hersey, A.; Nunhuck, S.; Keri, G.; Bevan, C. Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning. J. Med. Chem. 2006, 49, 6958-6971. (Pubitemid 44885984)
34. Lan, T; Rao, A; Haywood, J; Davis, C. B.; Han, C; Garver, E; Dawson, P. A. Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides. Drug Metab. Dispos. 2009, 37, 2375-2382.
35. Valko, K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J. Chromatogr., A 2004, 1037, 299-310. (Pubitemid 38591346)
36. Yokogawa, K.; Ishizaki, J.; Ohkuma, S.; Miyamoto, K. Influence of lipophilicity and lysosomal accumulation on tissue distribution kinetics of basic drugs: a physiologically based pharmacokinetic model. Methods Find. Exp. Clin. Pharmacol. 2002, 24, 81-93. (Pubitemid 34310988)
37. de Duve, C.; de Barsy, T.; Poole, B.; Trouet, A.; Tulkens, P.; Van, H. F. Commentary. Lysosomotropic agents. Biochem. Pharmacol. 1974, 23, 2495-2531.
38. Trapp, S.; Rosania, G. R.; Horobin, R. W.; Kornhuber, J. Quantitative modeling of selective lysosomal targeting for drug design. Eur. Biophys. J. 2008, 37, 1317-1328.
39. Duvvuri, M.; Krise, J. P. A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. Mol. Pharmaceutics 2005, 2, 440-448. (Pubitemid 43016385)
40. Moor, M. J.; Steiner, S. H.; Jachertz, G.; Bickel, M. H. Adipose tissue distribution and chemical structure of basic lipophilic drugs: desipramine, N-acetyl desipramine, and haloperidol. Pharmacol. Toxicol. 1992, 70, 121-124.
41. Kaufmann, A. M.; Krise, J. P. Lysosomal sequestration of aminecontaining drugs: analysis and therapeutic implications. J. Pharm. Sci. 2007, 96, 729-746. (Pubitemid 46657864)
42. MacIntyre, A. C.; Cutler, D. J. The potential role of lysosomes in tissue distribution of weak bases. Biopharm. Drug Dispos. 1988, 9, 513-526.
43. Bright, G.M.;Nagel, A.A.; Bordner, J.;Desai, K.A.;Dibrino, J.N.; Nowakowska, J.; Vincent, L.; Watrous, R. M.; Sciavolino, F. C.; English, A. R. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a- homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J. Antibiot. (Tokyo) 1988, 41, 1029-1047.
44. Mercep, M.; Mesic, M.; Tomaskovic, L.; Markovic, S.; Makaruha, O.; Poljak, V. Preparation of Steroid-Containing Macrolide Erythromycin Analog Glycosides for Treatment of Inflammatory Diseases. WO 2004005310, 2004.
45. Munić, V; Kelnerić, Z; Mikac, L; Eraković Haber, V. Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur. J. Pharm. Sci. 2010, 41, 86-95.
46. McFarland, J. W.; Berger, C. M.; Froshauer, S. A.; Hayashi, S. F.; Hecker, S. J.; Jaynes, B. H.; Jefson, M. R.; Kamicker, B. J.; Lipinski, C. A.; Lundy, K. M.; Reese, C. P.; Vu, C. B. Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida. J. Med. Chem. 1997, 40, 1340-1346. (Pubitemid 27198081)
47. Bhattachar, S. N.; Wesley, J. A.; Seadeek, C. Evaluation of the chemiluminescent nitrogen detector for solubility determinations to support drug discovery. J. Pharm. Biomed. Anal. 2006, 41, 152-157.
48. Pan, L.;Ho, Q.;Tsutsui, K.;Takahashi, L. Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. J. Pharm. Sci. 2001, 90, 521-529.
49. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615-2623. (Pubitemid 34595232)
50. Quinlan, J. R. C4.5: Programs for Machine Learning; Morgan Kaufmann Publishers, Inc.: San Mateo, CA, 1993.
51. Cohen, J. Multiple regression as a general data-analytic system. Psychol. Bull. 1968, 70, 426-443.